Cronos Group (CRON) Projected to Release Earnings on Thursday

Cronos Group (NASDAQ:CRON) is projected to issue its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to announce earnings of $0.01 per share and revenue of $44.20 million for the quarter. Investors can find conference call details on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:30 AM ET.

Cronos Group (NASDAQ:CRON) last released its quarterly earnings data on Monday, May 11th. The company reported $0.01 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.01. Cronos Group had a negative net margin of 1.14% and a negative return on equity of 1.26%. The firm had revenue of $45.21 million for the quarter, compared to the consensus estimate of $42.20 million.

Cronos Group Trading Down 0.7%

Shares of NASDAQ:CRON opened at $2.81 on Wednesday. The business’s fifty day simple moving average is $2.77 and its 200-day simple moving average is $2.67. Cronos Group has a 12-month low of $2.00 and a 12-month high of $3.43. The company has a market capitalization of $1.04 billion, a PE ratio of 281.28 and a beta of 0.90.

Analyst Ratings Changes

CRON has been the topic of a number of analyst reports. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Cronos Group in a research report on Friday, May 29th. Wall Street Zen upgraded Cronos Group from a “hold” rating to a “buy” rating in a research note on Saturday, May 16th. Finally, TD Securities reaffirmed a “buy” rating on shares of Cronos Group in a report on Tuesday, May 12th. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $2.30.

Institutional Investors Weigh In On Cronos Group

Several hedge funds have recently added to or reduced their stakes in CRON. Pillsbury Lake Capital LLC acquired a new stake in Cronos Group during the 4th quarter worth about $4,837,000. Arrowstreet Capital Limited Partnership lifted its holdings in shares of Cronos Group by 1,135.6% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 1,108,131 shares of the company’s stock valued at $3,075,000 after buying an additional 1,018,448 shares during the period. Two Sigma Investments LP boosted its stake in shares of Cronos Group by 229.6% in the third quarter. Two Sigma Investments LP now owns 1,310,386 shares of the company’s stock worth $3,643,000 after buying an additional 912,773 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of Cronos Group by 84.6% in the first quarter. Goldman Sachs Group Inc. now owns 1,076,405 shares of the company’s stock worth $1,948,000 after buying an additional 493,161 shares during the last quarter. Finally, Millennium Management LLC boosted its stake in shares of Cronos Group by 56.0% in the third quarter. Millennium Management LLC now owns 1,056,445 shares of the company’s stock worth $2,935,000 after buying an additional 379,250 shares during the last quarter. 8.71% of the stock is owned by hedge funds and other institutional investors.

About Cronos Group

Cronos Group Inc is a Canadian cannabinoid company dedicated to the cultivation, production and distribution of cannabis and cannabidiol (CBD) products for both medical and adult-use markets. Headquartered in Toronto, Ontario, the company manages operations that span the full cannabis value chain, including breeding, greenhouse cultivation, extraction, product formulation and packaging. Cronos Group’s business model emphasizes innovation in product development and scalability in manufacturing to meet evolving regulatory and consumer demands.

The company’s branded portfolio includes Peace Naturals, which focuses on pharmaceutical-grade medical cannabis; Spinach, a line of adult-use cannabis oils and tinctures; and Cove, a range of wellness-oriented CBD offerings.